<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00247481</url>
  </required_header>
  <id_info>
    <org_study_id>D7913C00148</org_study_id>
    <secondary_id>1839IL/0148</secondary_id>
    <nct_id>NCT00247481</nct_id>
  </id_info>
  <brief_title>ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of
      ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>o To assess progression-free survival (PFS) in the ZD1839-treated group and the placebo-treated group.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To estimate the duration of response in the ZD1839-treated group and the placebo treated group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To estimate overall survival in the ZD1839-treated group and the placebo-treated group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>o To estimate time to treatment failure (TTF) in the ZD1839-treated group and the placebo treated group</measure>
  </secondary_outcome>
  <enrollment>77</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed breast cancer at a metastatic stage.

          -  Uni- or bi-dimensionally measurable lesions (10 mm or 20 mm) according to the Response
             Evaluation Criteria in Solid Tumours (RECIST) criteria

          -  World Health Organisation (WHO) performance status (PS) of 0 to 2

          -  Life expectancy of greater than 12 weeks

          -  Normal cardiac function (left ventricular ejection fraction [LVEF] by isotopic
             examination greater than or equal to 55%)

        Exclusion Criteria:

          -  Symptomatic lepto-meningeal metastasis

          -  Concomitant infectious disease

          -  Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  Incomplete healing from previous oncologic or other surgery

          -  Absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than
             100 x 109/L

          -  Serum creatinine greater than 1.5 times the ULRR or clearance &lt; 60 ml/min

          -  ALT or AST greater than 2.5 times the ULRR

          -  ALP &gt; 5 times the ULRR

          -  ALP &gt; 2.5 times the ULRR and ALT or AST greater than 1.5 times the ULRR
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca France Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Germain en Laye</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2005</study_first_submitted>
  <study_first_submitted_qc>November 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2005</study_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <keyword>Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

